A retrospective case-control study to assess the correlation of weight loss and GLP-1 analogs in patients with TYPE 2 diabetes
Background: Obesity, defined as a BMI of 30 kg/m² or above, has become a key driver of type 2 diabetes mellitus (T2DM), a condition linked to considerable morbidity, mortality, and healthcare resource utilization. While pharmacological management of T2DM continues to evolve, glucagon-like peptide-1 (GLP-1) analogs have...